Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew E Pink

Showing results (21-30 of 63) with videos related to

Pageof 7
Sort By:
JAMA Dermatology|March 3, 2021
Association of Patient Mental Health Status With the Level of Agreement Between Patient and Physician Ratings of Psoriasis SeverityEwan Carr, Satveer K Mahil, Anamaria Brailean, et al.
The British Journal of Dermatology|April 24, 2024
Dupilumab in chronic actinic dermatitis: a retrospective case seriesMarese O'Reilly, Alexandra Paolino, Pirunthan Pathmarajah, et al.
The Journal of Investigative Dermatology|March 18, 2011
PSENEN and NCSTN mutations in familial hidradenitis suppurativa (Acne Inversa)Andrew E Pink, Michael A Simpson, Glen W Brice, et al.
Dermatology and Therapy|March 16, 2023
Similarities and Differences in the Perception of Atopic Dermatitis Burden Between Patients, Caregivers, and Independent Physicians (AD-GAP Survey)Amy S Paller, Stephan Weidinger, Korey Capozza, et al.
The Journal of Dermatological Treatment|March 8, 2022
Use of systemic therapies in adults with atopic dermatitis: 12-month results from the European prospective observational study in patients eligible for systemic therapy for atopic dermatitis (EUROSTAD)Marjolein de Bruin-Weller, Andrew E Pink, Silvia M Ferrucci, et al.
American Journal of Clinical Dermatology|July 20, 2022
Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc AnalysisJonathan I Silverberg, David N Adam, Matthew Zirwas, et al.
The Journal of Dermatological Treatment|March 13, 2026
Healthcare resource use of patients with mild-moderate psoriasis on systemic treatments: a UK single-center longitudinal retrospective cohort studyElizaveta Gribaleva, Erin Barker, Neil Hansell, et al.
The Journal of Investigative Dermatology|March 8, 2023
Real-World Implementation and Outcomes of Adalimumab Therapeutic Drug Monitoring in Psoriasis: A National Specialized Center ExperienceAntony Raharja, Zehra Arkir, Giulia Rinaldi, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 16, 2025
Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis phase 3 studiesSonja Ständer, Sarina B Elmariah, Shawn G Kwatra, et al.
JAAD International|February 9, 2026
Set targets, assess response, intervene early to achieve minimal disease activity in atopic dermatitis (STRIVE AD): A modified Delphi consensus project to optimize management of atopic dermatitis in the United KingdomMaria Angeliki Gkini, Helen Alexander, Maria Barfoot, et al.
Pageof 7

Showing results (21-30 of 63) with videos related to

Sort By:
Pageof 7
JAMA Dermatology|March 3, 2021
Association of Patient Mental Health Status With the Level of Agreement Between Patient and Physician Ratings of Psoriasis SeverityEwan Carr, Satveer K Mahil, Anamaria Brailean, et al.
The British Journal of Dermatology|April 24, 2024
Dupilumab in chronic actinic dermatitis: a retrospective case seriesMarese O'Reilly, Alexandra Paolino, Pirunthan Pathmarajah, et al.
The Journal of Investigative Dermatology|March 18, 2011
PSENEN and NCSTN mutations in familial hidradenitis suppurativa (Acne Inversa)Andrew E Pink, Michael A Simpson, Glen W Brice, et al.
Dermatology and Therapy|March 16, 2023
Similarities and Differences in the Perception of Atopic Dermatitis Burden Between Patients, Caregivers, and Independent Physicians (AD-GAP Survey)Amy S Paller, Stephan Weidinger, Korey Capozza, et al.
The Journal of Dermatological Treatment|March 8, 2022
Use of systemic therapies in adults with atopic dermatitis: 12-month results from the European prospective observational study in patients eligible for systemic therapy for atopic dermatitis (EUROSTAD)Marjolein de Bruin-Weller, Andrew E Pink, Silvia M Ferrucci, et al.
American Journal of Clinical Dermatology|July 20, 2022
Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc AnalysisJonathan I Silverberg, David N Adam, Matthew Zirwas, et al.
The Journal of Dermatological Treatment|March 13, 2026
Healthcare resource use of patients with mild-moderate psoriasis on systemic treatments: a UK single-center longitudinal retrospective cohort studyElizaveta Gribaleva, Erin Barker, Neil Hansell, et al.
The Journal of Investigative Dermatology|March 8, 2023
Real-World Implementation and Outcomes of Adalimumab Therapeutic Drug Monitoring in Psoriasis: A National Specialized Center ExperienceAntony Raharja, Zehra Arkir, Giulia Rinaldi, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 16, 2025
Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis phase 3 studiesSonja Ständer, Sarina B Elmariah, Shawn G Kwatra, et al.
JAAD International|February 9, 2026
Set targets, assess response, intervene early to achieve minimal disease activity in atopic dermatitis (STRIVE AD): A modified Delphi consensus project to optimize management of atopic dermatitis in the United KingdomMaria Angeliki Gkini, Helen Alexander, Maria Barfoot, et al.
Pageof 7